WallFlex™ Biliary RX Stent System
Device Facts
| Record ID | K223469 |
|---|---|
| Device Name | WallFlex™ Biliary RX Stent System |
| Applicant | Boston Scientific Corporation |
| Product Code | FGE · Gastroenterology, Urology |
| Decision Date | Jun 15, 2023 |
| Decision | SESU |
| Submission Type | Traditional |
| Regulation | 21 CFR 876.5010 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The WallFlex Biliary RX Stent system is in the palliative treatment of biliary strictures produced by malignant neoplasms, and relief of malignant biliary obstructions prior to surgery.
Device Story
WallFlex Biliary RX Stent System is an implantable, self-expanding metal stent designed for endoscopic placement in the biliary system. The stent is constructed from platinum-cored Nitinol wires, available in uncovered, partially covered, or fully covered configurations using Permalume material. The device is pre-loaded onto a delivery system (194cm working length). It is used by physicians in a clinical or endoscopic setting to maintain patency in biliary ducts obstructed by malignant neoplasms. By providing a mechanical scaffold, the stent relieves obstructions, facilitating palliative care or pre-surgical management. The physician navigates the delivery system to the target site, deploys the self-expanding stent, and removes the delivery catheter. The stent remains in situ to provide long-term relief of biliary obstruction.
Clinical Evidence
Bench testing only. Performance testing was conducted in accordance with FDA guidance for Metal Expandable Biliary Stents, Nitinol-containing devices, and MR environment safety. No clinical data was required or provided.
Technological Characteristics
Self-expanding metal stent; materials: platinum-cored Nitinol wires, Permalume (silicone) covering. Delivery system: 194cm length, 9Fr diameter. Deployment: endoscopic. Sterilization: not specified. Connectivity: none. Software: none.
Indications for Use
Indicated for palliative treatment of biliary strictures caused by malignant neoplasms and relief of malignant biliary obstructions prior to surgery in patients requiring endoscopic biliary stenting.
Regulatory Classification
Identification
A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.
Special Controls
*Classification.* Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
Predicate Devices
- WallFlex™ Biliary RX Stent System (K140630)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size below that.
June 15, 2023
Boston Scientific Corporation Alexis Erazo Principal Regulatory Affairs Specialist 200 Boston Scientific Way, Mail StopM41 Marlborough, MA 01752
Re: K223469
Trade/Device Name: WallFlex™ Biliary RX Stent System Regulation Number: 21 CFR 876.5010 Regulation Name: Biliary catheter and accessories Regulatory Class: Class II Product Code: FGE Dated: May 18, 2023 Received: May 18.2023
Dear Alexis Erazo:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
The OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
- 1. The safety and effectiveness of this device for use in the vascular system has not been established.
{1}------------------------------------------------
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products): good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medicaldevice-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products. including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn).
{2}------------------------------------------------
Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumereducation-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Courtney H. Lias -S
Courtney H. Lias, Ph.D. Office Director OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
# Indications for Use
510(k) Number (if known)
Device Name WallFlex Biliary RX Stent System
Indications for Use (Describe)
The WallFlex Biliary RX Stent system is in the palliative treatment of biliary strictures produced by malignant neoplasms, and relief of malignant biliary obstructions prior to surgery.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
# SECTION 5. 510(K) Summary
# 510(K) Summary [Per 21 CFR 807.92]
#### Submitter
Boston Scientific Corporation 100 Boston Scientific Way Marlborough, MA 01752
Primary Contact: Alexis Erazo Principal Regulatory Affairs Specialist 508.382.0365 alexis.erazo@bsci.com
Date Prepared: November 16, 2022
## Device Information
| Trade name: | WallFlex™ Biliary RX Stent System |
|----------------------|---------------------------------------------------|
| Device Common Name: | Biliary Catheter and Accessories |
| Classification Name: | Stents, Drains and Dilators for The Biliary Ducts |
| Regulation Number: | 21 CFR 876.5010 |
| Product Code: | FGE |
| Classification: | Class II |
| Panel: | Gastroenterology/Urology |
#### Predicate Device Information
| Trade name: | WallFlex™ Biliary RX Stent System |
|----------------------|---------------------------------------------------|
| 510(K) Number: | K140630 |
| Device Common Name: | Biliary Catheter and Accessories |
| Classification Name: | Stents, Drains and Dilators for The Biliary Ducts |
| Regulation Number: | 21 CFR 876.5010 |
| Product Code: | FGE |
| Classification: | Class II |
| Panel: | Gastroenterology/Urology |
{5}------------------------------------------------
## Device Description
The WallFlex™ Biliary RX Stent System is an implantable biliary self-explaining metal stent that is pre-loaded onto a Delivery System with a working length of 194cm, which allows delivery of the stent into the Biliary system endoscopically. The self-expanding metal stent consists of Platinum cored Nitinol wires wound together to form a cylinder including flares on both the proximal and distal ends. WallFlex™ Biliary RX Stent is available uncovered, partially covered, or fully covered with a Permalume™ covering.
#### Indications for Use
The WallFlex Biliary RX Stent System is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms, and relief of malignant biliary obstructions prior to surgery.
## Technological Characteristics
The proposed WallFlex Biliary RX Stent System and the previously cleared and currently marketed predicate WallFlex Biliary RX Stent System (K140630) have similar technological characteristics. The variations between the proposed WallFlex Biliary RX Stent System and the predicate device are the covering configurations and the dimensions of the delivery system. The predicate WallFlex Biliary Stents are available in a 100mm length without a covering. The proposed WallFlex Biliary Stents are 100mm length in either a partial silicone covered (PC) configuration, or a full silicone covered (FC) configuration. The Permalume covering is identical to the predicate partially or fully covered devices available in a 40mm, 60mm and 80mm stent length.
The proposed 100mm PC and FC WallFlex Biliary Stent System use a slightly larger 9Fr delivery system as the covering adds additional volume of material requiring a delivery system with a slightly larger outer diameter. Although the French size is different, the materials, length and method of delivery is identical to the predicate.
## Performance Data
Performance testing for the proposed WallFlex™ Biliary RX Stent System with 100mm Partially Covered (PC) and Fully Covered (FC) configurations was completed in accordance with the following FDA Guidance documents:
- Metal Expandable Biliary Stents Premarket Notification (510(k)) Submissions, issued . on July 27, 2019
- . Technical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol, issued on July 9, 2021
- Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) . Environment, issued on May 20, 2021
{6}------------------------------------------------
## Conclusion
Boston Scientific Corporation has demonstrated that the proposed WallFlex™ Biliary RX Stent System in 100mm PC and FC configurations are substantially equivalent to the previously cleared and currently marketed predicate WallFlex™ Biliary RX Stent System (K140630). The substantial equivalence of the subject device was determined as per the FDA guidance document, "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]."
The proposed and predicate devices have the same technological characteristics, indications for use, materials, and do not raise different questions of safety and effectiveness. The testing performed on the proposed WallFlex™ Biliary RX Stent System demonstrates the devices are substantially equivalent.
